BDX vs CNMD

Key Takeaways

• BDX holds a significantly larger market capitalization of $42.47 billion compared to CNMD's $1.11 billion, offering greater scale and stability.
• Both stocks operate in the medical devices sector, but BDX shows superior profitability with an 8.01% profit margin versus CNMD's 4.00%.
• BDX exhibits lower volatility with a beta of 0.28 (a measure of stock price sensitivity to market movements), contrasting CNMD's higher beta of 0.94.
• Year-to-date (YTD), BDX has gained 1.51% while CNMD has declined approximately 5.92%.
• Recent earnings for both reflect sector challenges, with BDX posting Q1 revenue of $5.25 billion amid expected Q2 softness, and CNMD beating Q4 sales estimates but facing share price pressure.

Introduction

This stock comparison examines BDX and CNMD, two players in the medical technology sector focused on devices and supplies. Investors seeking exposure to healthcare innovation, particularly in surgical and diagnostic tools, may find value in analyzing their relative performance. Traders monitoring relative strength in a volatile market environment can use this head-to-head to gauge momentum, valuation trade-offs, and sector positioning. With both stocks navigating recent earnings cycles and macroeconomic pressures, understanding their contrasts aids informed decision-making in portfolio allocation or short-term trades.

BDX Overview and Recent Performance

Becton, Dickinson and Company (BDX) is a global leader in developing, manufacturing, and selling medical devices, laboratory equipment, and diagnostic products across segments like Medical Essentials, Connected Care, and Life Sciences. In recent market activity, shares have traded near the lower end of their 52-week range of $127.59 to $187.35, reflecting broader sector caution following mixed quarterly results. Q1 fiscal 2026 revenue reached $5.25 billion with net income of $831.81 million, though analysts anticipate Q2 declines in earnings per share (EPS, a measure of profitability per share) and revenue amid supply chain headwinds and softer demand. Positive sentiment drivers include product innovations in vascular access and employee well-being recognitions, alongside a steady dividend declaration, supporting resilience in a challenging environment.

CNMD Overview and Recent Performance

CONMED Corporation (CNMD) specializes in surgical devices and equipment for minimally invasive procedures, targeting orthopedics, general surgery, and other specialties. In recent weeks, the stock has experienced downward pressure, underperforming broader indices with YTD declines around 5.92% and heightened volatility. Shares hover near recent lows amid a 52-week range reflecting sharp drops. Q4 CY2025 results exceeded revenue expectations with 7.9% year-over-year growth, yet subsequent quarters highlighted slowing demand and valuation concerns. Factors influencing sentiment include analyst price target reductions and comparisons to peers, tempered by projections for 5.2% long-term earnings growth. Recent trading shows weekly declines, underscoring sensitivity to market rotations away from smaller-cap medtech names.

Trending AI Robots

Tickeron’s Trending AI Robots page curates 25 top-performing AI trading bots from over 351 available, each scanning thousands of tickers for real-time signals suited to current market conditions like AI infrastructure booms, volatility plays, and sector rotations. These bots employ diverse strategies—ranging from short-term scalping (5-60 minutes) to swing trades—delivering impressive stats such as annualized returns of +30% to +163%, win rates of 50-88%, profit factors from 1.5 to 7+, and profit-to-drawdown ratios up to 17. Focused on high-momentum areas like semiconductors, data centers, and small caps, they have outperformed the S&P 500 in recent months. Explore these bots to align automated trading with prevailing trends across various timeframes and risk profiles.

Head-to-Head Comparison

BDX and CNMD both serve the medtech space but differ in scale and focus: BDX’s diversified portfolio spans diagnostics and infusion systems for broad healthcare exposure, while CNMD emphasizes niche surgical tools with higher growth potential but execution risks. Valuation metrics highlight BDX’s trailing price-to-earnings (P/E, stock price relative to EPS) ratio of 24.4 versus CNMD’s 20.8, though CNMD trades at a lower price-to-sales multiple of 0.83. Recent momentum favors neither strongly, with both facing YTD softness, but BDX’s lower beta signals reduced risk amid market swings. Growth drivers for BDX include innovation pipelines, while CNMD contends with demand slowdowns; sentiment tilts toward BDX’s return on equity (ROE, profitability relative to shareholders' equity) of 6.96% over CNMD’s 5.50%.

Tickeron AI Verdict

Tickeron’s AI analysis leans toward BDX in the current environment, citing its superior scale, higher margins, lower volatility, and trend stability relative to CNMD. Factors like consistent revenue execution and defensive beta position BDX favorably amid sector headwinds, though CNMD could rebound on earnings beats. This probabilistic edge reflects observable momentum and risk-reward dynamics rather than guarantees.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations